The use of modified-release methylphenidate in the treatment of attention-deficit/hyperactivity disorder.

The use of modified-release methylphenidate in the treatment of attention-deficit/hyperactivity disorder.

Expert Rev Neurother. 2016 Dec 11;

Authors: Childress A, Belchenko D, Lempa B

Abstract
INTRODUCTION: Since Ritalin® (Methylphenidate-Immediate release or MPH-IR) was introduced for the treatment of attention-deficit/hyperactivity disorder, multiple formulations of MPH have been developed. The specific formulation determines the pharmacokinetic (PK) profile and the onset and duration of action for the compound.
AREAS COVERED: Aptensio XR® is a multilayer-release MPH (MPH-MLR) consisting of an MPH-IR layer (40%) and an extended-release (ER) portion of 60% of MPH. It has an initial maximum MPH concentration at about two hours (h) and a second concentration peak at approximately 8h. This formulation allows for a rapid onset of effect by 1h and a duration of action through 12h after dosing. The chemistry, PK, efficacy and adverse event profile of MPH-MLR will be reviewed.
EXPERT COMMENTARY: Although the PK profile may prove beneficial to patients in the late afternoon and early evening, it is not clear if this is an advantage compared with other MPH-ER formulations.

PMID: 27936986 [PubMed – as supplied by publisher]

via https://www.ncbi.nlm.nih.gov/pubmed/27936986?dopt=Abstract